Headlines

Gilead (GILD) says they have reached guidance number for Yeztugo in 2025 of USD 150mln after the launch in the middle of 2025, via JPM Conference

Newsquawk Staff ·

  • Filed Anito-cel with FDA, awaiting a confirmation of acceptance letter they expect this quarter, and targeting launch for h2 2026

What it means

Gilead's guidance for Yeztugo at $150 million by 2025 marks a commitment to their biotech growth, indicating optimism post-launch. While the projection reflects confidence, it's crucial to assess their FDA filing acceptance and market dynamics leading up to the product launch, as these factors will significantly shape investor sentiment and stock performance.

Related headlines